Navigation Links
Carl Zeiss Continues on Track to Further Growth and Investment
Date:12/13/2012

STUTTGART, Germany, December 13, 2012 /PRNewswire/ --

Strong Portfolio Offsets Cyclical Fluctuations in the Semiconductor Manufacturing Technology Business Group

The Carl Zeiss Group ended fiscal year 2011/12 with a two percent increase in revenue to a total of EUR 4.163 billion (prior year*: EUR 4.084 billion). EBIT totaled EUR 420 million (prior year*: EUR 608 million). "2011/12 was a very successful fiscal year for Carl Zeiss. "We have surpassed the figure we forecast last year: revenue is slightly above the equivalent total in the prior year," said Dr. Michael Kaschke, President and CEO of Carl Zeiss. "What is particularly notable is that our strong portfolio has enabled us to successfully offset the cyclical downturn in the revenue of the Semiconductor Manufacturing Technology business group. This would not have been possible just a few years ago."  

In 2011/12 Carl Zeiss hired 900 new recruits worldwide and increased its investments in research and development by 14 percent. Investments in property, plant and equipment totaled EUR 289 million, allowing the company to modernize and expand its global infrastructure.

*Calculated on a like-for-like basis

More information at http://www.zeiss.de/press

Carl Zeiss

The Carl Zeiss Group is an international leader in the fields of optics and optoelectronics. In fiscal year 2011/12 the company's approx. 24,000 employees generated revenue of about 4.163 billion euros. In the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, Carl Zeiss has contributed to technological progress all over the world for more than 160 years.

The Carl Zeiss Group develops and produces planetariums, eyeglass lenses, camera and cine lenses and binoculars as well as solutions for biomedical research, medical technology and the semiconductor, automotive and mechanical engineering industries. Carl Zeiss is
'/>"/>

SOURCE Carl Zeiss AG
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Accelr8 to Hold 2012 Annual Meeting of Shareholders; Product Development Continues with Launch Expected in 2015
2. FUJIFILM Continues To Build 3D Digital Roadmap To Womans Imaging
3. Fujifilm Continues To Grow Its Family Of DR Portables
4. Isis To Receive $1.25 Million Payment As Pfizer Continues Development Of EXC 001
5. Philips continues to improve access to treatment for common cause of death in the U.S. with the delivery of its one-millionth AED
6. PathGroup Unveils a New Look; Continues to Expand Footprint
7. Brainlab Continues to Advance Global Treatment Access and Consistency in Cancer Care Centers
8. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
9. Top OTC Brand deploys Semantelli AETracker to monitor Adverse Events in Facebook
10. Novo Nordisk introduces HemaGo, a mobile application to track hemophilia treatment, bleeding episodes and life events
11. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... BAUDETTE, Minn., Aug. 4, 2015 ANI Pharmaceuticals, ... results for the three and six months ended June ... The Company will host its earnings conference call this ... and other interested parties can join the call by ... Year-to-Date Highlights Include: , Year-to-date net revenues ...
(Date:8/3/2015)... , Aug. 4, 2015   The Intellectual ... the world,s leading provider of intelligent information for ... 2015 CMR Pharmaceutical R&D Factbook , the ... Despite concerns around declines in R&D, the analysis ... $1 trillion milestone and forecasts sales to reach ...
(Date:8/3/2015)... (NASDAQ: LMNX ) today announced financial results for ... operating highlights for the quarter include the following: ... percent to $58.9 million, over the second quarter of ... by 22 percent to $24.2 million over results from ... 2015 royalty revenue by 17 percent to $11.1 million ...
Breaking Medicine Technology:ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 4ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 5ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 6ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 7ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 8ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 9ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 10ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 11ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 12ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 13ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 14ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 15ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 16Pharma Sales to Grow Beyond $1 Trillion 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 3Luminex Corporation Reports Record 2nd Quarter 2015 Results 4Luminex Corporation Reports Record 2nd Quarter 2015 Results 5Luminex Corporation Reports Record 2nd Quarter 2015 Results 6Luminex Corporation Reports Record 2nd Quarter 2015 Results 7Luminex Corporation Reports Record 2nd Quarter 2015 Results 8Luminex Corporation Reports Record 2nd Quarter 2015 Results 9Luminex Corporation Reports Record 2nd Quarter 2015 Results 10Luminex Corporation Reports Record 2nd Quarter 2015 Results 11Luminex Corporation Reports Record 2nd Quarter 2015 Results 12Luminex Corporation Reports Record 2nd Quarter 2015 Results 13Luminex Corporation Reports Record 2nd Quarter 2015 Results 14Luminex Corporation Reports Record 2nd Quarter 2015 Results 15Luminex Corporation Reports Record 2nd Quarter 2015 Results 16
... Allon Therapeutics Inc. (TSX: NPC), today announced that ... RetailInvestorConferences.com.DATE: , March 3rd, 2011TIME: , 3:00 ... live, interactive online event where investors are invited to ... presentation hall as well as the company,s "virtual trade ...
... Cellectis bioresearch, a specialist in genome customization and ... Access™, the first fee-for-service custom TALEN(1). Recognized ... products for genome customization, Cellectis bioresearch brings today the ... genes in any type of cell. The ...
Cached Medicine Technology:Allon Therapeutics to Present Live, Online at RetailInvestorConferences.com on March 3rd 2Allon Therapeutics to Present Live, Online at RetailInvestorConferences.com on March 3rd 3Cellectis bioresearch Makes Genome Engineering Affordable for All Users 2
(Date:8/4/2015)... ... August 04, 2015 , ... Wimbledon Health Partners , ... NCV testing, announced their collegiate division, Wimbledon U , continues to not ... program at a time. , “Wimbledon U welcomes the eight new ...
(Date:8/4/2015)... ... ... An article published July 27th by the Providence Journal detailed ... people to lose weight. Specifically the study compared control patients with those who were ... financial incentive to the overall incentive of increased health. According to Michael Feiz, M.D., ...
(Date:8/4/2015)... , ... August 04, 2015 , ... Bayco Products, Inc. ... enough to fit, for example, on hard hats that have a flip-up face shield. ... allows users to work without having to remove their headlamp when raising or ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, CA ... only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands in ...
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide Power Products acquires new ... its reach in Texas. Effective July 1st of this year, Worldwide Power Products ... With the North Texas acquisition, Worldwide Power Products (“WPP”) now services 1000 ...
Breaking Medicine News(10 mins):Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:North Texas Acquisition Press Release 2
... named REACH: Registration, Evaluation and Authorization of Chemicals, has shifted ... manufacturers. ,The chemical companies would be bound by ... of their business. ,This law aims to make ... safe for users and the environs. ,The European ...
... Surgical Adjuvant Breast and Bowel Project (NSABP) B-33 ... Cancer Symposium, showed that// postmenopausal women with hormone ... years of tamoxifen were 56% less likely to ... who received placebo (P=0.004). ,“Aromasin provided ...
... in occupational settings and in the environment has been ... Journal of Occupational and Environmental Medicine, official publication of ... is a special issue providing updates on particles and ... types of studies for some particles in terms of ...
... soy-based substance. A US based study finds: BBIC improves ... multiple// sclerosis. ,A group of animals with ... animals also suffering from the same disease received a ... to walk, while those that didn't get the drug ...
... the Bombay Hospital and three other firms are planning to ... ,The Jaipur Development Authority would allot land for the five ... a Rs.2 billion Medi-City to be built here in three ... ,The state plans to be strict with the investors ...
... In the absence of vaccine against HIV/AIDS, the 'social vaccine' ... of the deadly virus, a top UN official here said ... to fight against the HIV/AIDS," said Peter Piot, executive director ... vaccine I mean to create a mass awareness to educate ...
Cached Medicine News:Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 2Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 3Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 4Health News:Inhaled Particles Increases the Risk of Lung Cancer 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: